Orchard Therapeutics PLC

Orchard Therapeutics — Conference Presentation (January 2020)

27 slides from Orchard Therapeutics's conference presentation, Jan 13, 2020

  1. Slide 1: Dedicated to Transforming the Lives of Patients Through Innovative Gene Therapies

    Dedicated to Transforming the Lives of Patients Through Innovative Gene Therapies January 13 - 15, 2020 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements | Certain information set forth in this presentation and in statements made orally during this presentation contains “forward-looking statements”. Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, bu

  3. Slide 3: Global gene therapy company dedicated to patients with rare diseases

    Global gene therapy company Dedicated to transforming the lives of patients with rare diseases Focused today on ex-vivo autologous HSC gene therapy | Confidential Orchard Therapeutics

  4. Slide 4: The Orchard Therapeutics Story: Strong Fundamentals

    | THE ORCHARD THERAPEUTICS STORY Strong Momentum – Transformative Year Ahead 1 Strong Fundamentals 2 Powerful Platform Approach 3 Commercial Ready 4 Our Future

  5. Slide 5: Compelling Fundamentals Driving Near and Long-term Growth

    Compelling Fundamentals Driving Near and Long-term Growth | Highly leverageable platform approach to gene therapy; potential to address numerous rare diseases Strong balance sheet (~$325M as of YE 2019) to fund the business into the second half of 2021 1Based on target label and pricing of recent ge

  6. Slide 6: One of the Deepest Pipelines in Gene Therapy

    One of the Deepest Pipelines in Gene Therapy MAA decision BLA late 2020 / early 2021 Initiate rolling BLA 1H 2020 MAA & BLA submissions 2021 Interim POC data - 2020 Interim POC data - 2020 |

  7. Slide 7: Building a Scalable Business in Rare Diseases

    Building a Scalable Business in Rare Diseases | 1Based on target label and pricing of recent gene therapy analogs Incidence / prevalence figure estimates based on available literature, population data and in-house estimates, in countries where rare disease therapies are typically reimbursed. Higher

  8. Slide 8: Annual Incidence

    Annual Incidence 80% 80% 80% | 1Based on target label and pricing of recent gene therapy analogs Incidence / prevalence figure estimates based on available literature, population data and in-house estimates, in countries where rare disease therapies are typically reimbursed. Higher incidence rates h

  9. Slide 9: The Orchard Therapeutics Story: Powerful Platform Approach

    | THE ORCHARD THERAPEUTICS STORY Strong Momentum – Transformative Year Ahead 1 Strong Fundamentals 2 Powerful Platform Approach 3 Commercial Ready 4 Our Future

  10. Slide 10: HSC Gene Therapy Offers a Highly Differentiated Approach

    HSC Gene Therapy Offers a Highly Differentiated Approach | Integration Self-renewal One-time administration Monocyte / Macrophage / Microglia T cells B cells NK cells Megakaryocyte Erythrocyte Granulocyte Potential for permanent disease correction Differentiates into multiple cell types

  11. Slide 11: Potential to Correct Multiple Cell Types Addresses Many Rare Diseases

    Potential to Correct Multiple Cell Types Addresses Many Rare Diseases | Immune System MLD MPS-I MPS-IIIA MPS-IIIB ADA-SCID WAS X-CGD WAS TDT Monocyte / Macrophage / Microglia T cells B cells NK cells Megakaryocyte Erythrocyte Granulocyte Central Nervous System Immune System Blood Cell and Platelet L

  12. Slide 12: Durability of Response Out to 18+ Years

    Durability of Response Out to 18+ Years with > 170 Patients Treated | Patients treated in the development phase, including in clinical trials and under pre-approval access (defined as any form of pre-approval treatment outside of a company-sponsored clinical trial, including, but not limited to, com

  13. Slide 13: The Orchard Therapeutics Story: Commercial Ready

    | THE ORCHARD THERAPEUTICS STORY Strong Momentum – Transformative Year Ahead 1 Strong Fundamentals 2 Powerful Platform Approach 3 Commercial Ready 4 Our Future

  14. Slide 14: Metachromatic Leukodystrophy is a Devastating, Rapidly Progressive Disease

    Metachromatic Leukodystrophy is a Devastating, Rapidly Progressive Disease | Disease Snapshot Fatal genetic CNS disorder Relentless loss of physical and cognitive function Presents on a spectrum with different ages of onset Age 5, pre-diagnosis Age 9, advanced disease

  15. Slide 15: Significantly Superior Motor and Cognitive Function vs. Natural History

    Significantly Superior Motor and Cognitive Function Demonstrated vs. Natural History | Both LI and EJ patients achieved a statistically significant difference on the co-primary endpoint of improvement of >10% of the total GMFM score in treated subjects when compared to the Natural History cohort at

  16. Slide 16: Implementing Commercial Strategy to Launch OTL-200 Globally

    Implementing Commercial Strategy to Launch OTL-200 Globally | Market Access 4 Multi-stakeholder engagement Gene therapy value determination Option for flexible payment models Patient ID and Diagnostics 1 Disease awareness and diagnostic testing Extensive newborn screening pilot testing efforts in EU

  17. Slide 17: Multi-Pronged Approach to Identifying MLD Patients

    Multi-Pronged Approach to Identifying MLD Patients Confidential | Disease and Diagnostic Education Diagnostic Initiatives Newborn Screening Patient Identification Identify first symptoms and drive early suspicion KOL engagement and education of general pediatricians Peer to peer education Assay deve

  18. Slide 18: Establish Commercial and Operational Model: Phase 1

    Establish Commercial and Operational Model: Building Teams and Infrastructure to Serve Patients Worldwide | Middle East includes GCC countries and Israel Phase 1 - 2019 / 2020 EU, Middle East 25 commercial FTEs 4 - 6 treatment centers planned Newborn screening pilots initiating (EU & U.S.) Penetrati

  19. Slide 19: Establish Commercial and Operational Model: Phase 2

    Establish Commercial and Operational Model: Building Teams and Infrastructure to Serve Patients Worldwide | Middle East includes GCC countries and Israel Phase 2 - 2020 / 2021 U.S. Penetration and reimbursement varies by market

  20. Slide 20: Establish Commercial and Operational Model: Phase 3

    Establish Commercial and Operational Model: Building Teams and Infrastructure to Serve Patients Worldwide | Middle East includes GCC countries and Israel Phase 3 - 2021 / 2022 LatAm, ROW Penetration and reimbursement varies by market

  21. Slide 21: Manufacturing in Place to Support Commercialization

    Manufacturing in Place to Support Commercialization | MolMed producing drug product and vector Sufficient inventory being produced to meet expected launch demand Leveraging commercial process experience from Strimvelis CMO Infrastructure Established for Initial MLD Launch NEAR TERM Continue partners

  22. Slide 22: Drive Global Access: Our Pricing Commitments

    Drive Global Access: Our Pricing Commitments | Shared value Ensure patients, society and industry share in human and economic benefits of innovation – now and in the future Shared risk Stand behind therapeutic outcomes and be willing to tie payment to outcomes Informed pricing Use demonstrable, obje

  23. Slide 23: The Orchard Therapeutics Story: Our Future

    | THE ORCHARD THERAPEUTICS STORY Strong Momentum – Transformative Year Ahead 1 Strong Fundamentals 2 Powerful Platform Approach 3 Commercial Ready 4 Our Future

  24. Slide 24: Investment to Scale and Innovate Across Our Business

    Investment to Scale and Innovate Across Our Business | PRODUCT PROCESS Transduction enhancers Non-toxic conditioning HSC subsets Stable cell line Closed automated systems Manufacturing facility (expected operational in 2021) Research and discovery for new indications in 2020 Technology innovations I

  25. Slide 25: Gene-corrected HSCs and Macrophage Progeny Can Address Brain and Other Organ Disorders

    Gene-corrected HSCs and Macrophage Progeny Can Address Brain and Other Organ System Disorders | Other rare indications Potential non-rare (longer-term) Other Organ Systems Brain Macrophage High area of focus Potential future exploration Literature references: Alessia Capotondo, Rita Milazzo, Letteri

  26. Slide 26: Building on our Strength in Neurometabolic Disorders

    Building on our Strength in Neurometabolic Disorders | MPS-IIIB Preclinical MPS-I MPS-IIIA Interim POC data in 2020 MLD Pre-commercial / filed with EMA Multiple new neurodegenerative disorders Potential applications in larger / non-rare conditions Brain Research Undisclosed External collaboration Dr

  27. Slide 27: Corporate Priorities & Expected Key Milestones

    Corporate Priorities & Expected Key Milestones | ADA-SCID Initiate a rolling BLA in the U.S. for OTL-101 in 1H 2020 with completion within 12 months MLD Submit a BLA filing in late 2020 or early 2021 Obtain approval and launch OTL-200 for MLD in Europe in 2H 2020 MPS-I Release interim data from POC

Orchard Therapeutics — Conference Presentation (January 2020) on 6ix